How do microtubule-targeted drugs work? An overview

Current Cancer Drug Targets

Volumn 7, Issue 8, 2007, Pages 730-742

  Jordan, Mary Ann ^a   Kamath, Kathy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Drugs; Dynamic instability; Microtubules; Mitosis; Taxol; Tubulin; Vinblastine

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AURISTATIN PE; BMS 188797; BMS 844476; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; CRYPTOPHYCIN 52; DISCODERMOLIDE; DOCETAXEL; E 7389; EPOTHILONE B; EPOTHILONE D; ESTRAMUSTINE; HALICHONDRIN; IXABEPILONE; KOS 1584; LAROTAXEL; MAYTANSINOID; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHICINOL O PHOSPHATE; N ACETYLCOLCHINOL PHOSPHATE; NAVELBINE; NOSCAPINE; NPI 2358; PACLITAXEL; PACLITAXEL DERIVATIVE; PIPERAZINEDIONE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TALTOBULIN; TL 00139; TPI 287; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE SULFATE; VINFLUNINE; XRP 6258;

ACTINIC KERATOSIS; ANTIANGIOGENIC ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CELL SPECIFICITY; CLINICAL TRIAL; COLON CANCER; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; FAMILIAL MEDITERRANEAN FEVER; GERM CELL TUMOR; GLIOBLASTOMA; GOUT; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MICROTUBULE; MITOSIS INHIBITION; MULTIPLE MYELOMA; OVARY CARCINOMA; PANCREAS CANCER; PHARMACODYNAMICS; PROSTATE CANCER; REVIEW; SOLID TUMOR; TISSUE SPECIFICITY;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; MICROTUBULES; TUBULIN;

EID: 37449001322     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907783220417     Document Type: Review

References (168)

1. Giannakakou, P.; Sackett, D.; Fojo, T. Tubulin/Microtubules: Still a Promising Target for New Chemotherapeutic Agents. J. Natl. Cancer Inst. 2000, 92,182-183.
2. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
3. Duflos, A.; Kruczynski, A.; Barret, J. -M. Novel aspects of natural and modified Vinca alkaloids. Curr. Med. Chem. Anti-Cancer Agents 2002, 2, 55-70.
4. Mano, M. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treat. Rev. 2006, 32, 106-118.
5. Bennouna, J.; Campone, M.; Delord, J.; Pinel, M. Vinflunine: a novel antitubulin agent in solid malignancies. Exp. Opin. Investig. Drugs 2005, 14, 1259-1267.
6. Hill, B. T. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr. Pharm. Des. 2001, 7(13), 1199-1212.
7. D'Agostino, G.; del Campo, J.; Mellado, B.; Izquierdo, M.; Minarik, T.; Cirri, L.; Marini, L.; Perez-Gracia, J. L; Scambia, G. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int. J. Gynecol. Cancer 2006, 16, 71-76.
8. Jordan, M. A.; Kamath, K.; Manna, T.; Okouneva, T.; Miller, H.; Davis, C.; Littlefield, B. A.; Wilson, L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005, 4, 1086-1095.
9. Kuznetsov, G.; Towle, M. J.; Cheng, H. T. K.; TenDyke, K.; Liu, D.; Kishi, Y.; Yu, M.; Littlefield, B. A. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004, 64, 5760-5766.
10. Towle, M. J.; Salvato, K. A.; Budrow, J.; Wels, B. F.; Kuznetsov, G.; Aalfs, K. K.; Welsh, S.; Zheng, W.; Seletzky, B. M.; Palme, M. H.; Habgood, G. J.; Singer, L. A.; DiPietro, L. V.; Wang, Y.; Chen, J. J.; Quincy, D. A.; Davis, A.; Yoshimatsu, K.; Kishi, Y.; Yu, M. J.; Littlefield, B. A. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B. Cancer Res. 2001, 61, 1013-1021.
11. Shimoyama, T.; Hamano, T.; Natsume, T.; Koizumi, F.; Kiura, K; Tanimoto, M.; Nishio, K. Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro. Pharmacogenomics J. 2006, 6, 388-396.
12. Tozer, G.; Kanthou, C. B. C.; Baguley, B. Disrupting Tumour Blood Vessels. Nat. Rev. Cancer 2005, 5, 423-435.
13. Rasila, K.; Verschraegen, C. Tasidotin HCl (Genzyme). Curr. Opin. Investig. Drugs 2005, 6, 631-638.
14. Cunningham, C.; Appleman, L. J.; Kirvan-Visovatti, M.; Ryan, D. P.; Regan, E.; Vukelja, S.; Bonate, P. L.; Ruvuna, F.; Fram, R. J.; Jekunen, A.; Weitman, S.; Hammond, L. A.; Eder, J. P., Jr. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11, 7825-7833.
15. Rawat, D.; Joshi, M.; Joshi, P.; Atheaya, H. Marine peptides and related compounds in clinical trial. Anticancer Agents Med. Chem. 2006, 6, 33-40.
16. http://clinicaltrials.gov. Website for ongoing clinical trials. 2006.
17. Widdison, W.; Wilhelm, S. D.; Cavanagh, E. E.; Whiteman, K. R.; Leece, B. A.; Kovtun, Y.; Goldmacher, V. S.; Xie, H.; Steeves, R. M.; Lutz, R. J.; Zhao, R.; Wang, L.; Blattler, W. A; Chari, R. V. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392-4408.
18. Smith, S. Technology evaluation:Cantuzumab mertansine, Immunogen. Curr. Opin. Mol. Ther. 2004, 6, 666-674.
19. Cassady, J.; Chan, K.; Floss, H.; Leistner, E. Recent Developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. 2004, 52, 1-26.
20. Erickson, H.; Park, P. U.; Widdison, W. C.; Kovtun, Y. V.; Garrett, L. M.; Hoffman, K.; Lutz, R. J.; Goldmacher, V. S.; Blattler, W. A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006, 66, 4426-4433.
21. Kovtun, Y.; Audette, C. A.; Ye, Y.; Xie, H.; Ruberti, M. F.; Phinney, S. J.; Leece, B. A.; Chittenden, T.; Blattler, W. A; Goldmacher, V. S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006, 66, 3214-3221.
22. Russo, G. Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatment. Clin. Dermatol. 2005, 23, 581-586.
23. Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 2002, 83(1), 21-38.
24. Chaplin, D.; Horsman, M.; Siemann, D. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs 2006, 7, 522-528.
25. Mabjeesh, N. J.; Escuin, D.; LaVallee, T. M.; Pribluda, V. S.; Swartz, G. M.; Johnson, M. S.; Willard, M. T.; Zhong, H.; Simons, J. W.; Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3, 63-75.
26. Lakhani, N. J.; Sarkar, M. A.; Venitz, J.; Figg, W. D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003, 23, 165-172.
27. Kamath, K.; Okouneva, T.; Larson, G.; Panda, D.; Wilson, L.; Jordan, M. A. 2-Methoxyestradiol Suppresses Microtubule Dynamics and Arrests Mitosis without Depolymerizing Microtubules. Mol. Cancer Ther. 2006, 5, 2225-2233.
28. Mohan, R.; Banerjee, M.; Ray, A.; Manna, T.; Wilson L; Owa, T.; Bhattacharyya, B.; Panda, D. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry 2006, 45, 5440-5449.
29. Yee, K.; Hagey, A.; Verstovsek, S.; Cortes, J.; Garcia-Manero, G.; O'Brien, S.; Faderl, S.; Thomas, D.; Wierda, W.; Kornblau S.; Ferrajoli, A.; Albitar, M.; McKeegan, E.; Grimm, D.; Mueller, T.; Holley-Shanks, R. R.; Sahelijo, L.; Gordon, G.; Kantarjian, H.; Giles, F. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2005, 11, 6615-6624.
30. Nicholson, B.; Lloyd, G. K.; Miller, B. R.; Palladino, M. A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S. T. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006, 17, 25-31.
31. Diaz, J. F.; Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993, 32, 2747-2755.
32. Manfredi, J. J.; Parness, J.; Horwitz, S. B. Taxol binds to cell microtubules. J. Cell Biol. 1982, 94, 688-696.
33. Parness, J.; Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 1981, 91, 479-487.
34. Attard, G.; Greystoke, A.; Kaye, S; De Bono, J. Update on tubulin-binding agents. Pathol. Biol. (Paris) 2006, 54, 72-84.
35. Advani, R.; Fisher, G. A.; Lum, B. L.; Jambalos, C.; Cho, C. D.; Cohen, M.; Gollerkeri, A.; Sikic, B. I. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin. Cancer Res. 2003, 9, 5187-5194.
36. Dang, C.; Hudis, C. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. Clin. Breast Cancer 2006, 7, 51-58.
37. Belani, C. P.; Langer, C.; TAX 326 Study Group. T.S. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 2002, 38, 13-19.
38. Larkin, J.; Kaye, S. Epothilones in the treatment of cancer. Exp. Opin. Investig. Drugs 2006, 15, 691-702.
39. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
40. Wartmann, M.; Altmann, K. H. The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anti-Cancer Agents 2002, 2(1), 123-148.
41. Honore, S.; Kamath, K.; Braguer, D.; Horwitz, S.; Wilson, L.; Briand, C.; Jordan, M. A. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res. 2004, 64, 4957-4964.
42. Honore, S.; Kamath, K.; Braguer, D.; Wilson, L.; Briand, C.; Jordan, M. A. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol. Cancer Ther. 2003, 2, 1303-1311.
43. Hung, D. T.; Chen, J.; Schreiber, S. L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol. 1996, 3, 287-293.
44. Kavallaris, M.; Verrills, N. M.; Hill, B. T. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Updat. 2001, 4(6), 392-401.
45. Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 1997, 52, 613-622.
46. ter Haar, E.; Kowalski, R.; Hamel, E.; Lin, C.; Longley, R.; Gunasekera, S.; Rosenkranz, H.; Day, B. W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996, 35, 243-250.
47. Huang, G. S.; Lopez-Barcons, L.; Freeze, B. S.; Smith, III, A.; Goldberg, G. L.; Horwitz, S.; McDaid, H. Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin. Cancer Res. 2006, 12, 298-304.
48. Dahllof, B.; Billstron, A.; Cabral, F.; Hartley-Asp, B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 1993, 53, 4573-4581.
49. Hudes, G.; Haas, N.; Yeslow, G.; Gillon, T.; Gunnarsson, P.; Ellman, M.; Nordle, O.; Eriksson, B.; Miller, L.; Cisar, L.; Kopreski, M.; Viaro, D.; Hartley-Asp, B. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J. Clin. Oncol. 2002, 20, 1115-1127.
50. Hudes, G. R.; Nathan, F.; Khater, C.; Haas, N.; Cornfield, M.; Giantonio, B.; Greenberg, R.; Gomella, L.; Litwin, S.; Ross, E.; Roethke, S.; McAleer, C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1997, 15, 3156-3163.
51. Kelly, W.; Zhu, A.; Scher, H.; Curley, T.; Fallon, M.; Slovin, S.; Schwartz, L.; Larson, S.; Tong, W.; Hartley-Asp, B.; Pellizzoni, C.; Rocchetti, M. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin. Cancer Res. 2003, 9, 2098-2107.
52. Panda, D.; Miller, H.; Islam, K.; Wilson, L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action. Proc. Natl. Acad. Sci. USA 1997, 94, 10560-10564.
53. Smaletz, O.; Galsky, M.; Scher, H.; DeLaCruz, A.; Slovin, S.; Morris, M.; Solit, D.; Davar, U.; Schwartz, L.; Kelly, W. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann. Oncol. 2003, 14, 1518-1524.
54. Ling, Y.; Jiang, J.; Holland, J.; Perez-Soler, R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. 2002, 62, 529-538.
55. Carre, M.; Carles, G.; Andre, N.; Douillard, S.; Ciccolini, J.; Briand, C.; Braguer, D. Involvement of microtubule and mitochondria in the antogonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem. Pharmacol. 2002, 63, 1831-1842.
56. Landen, J. W.; Lang, R.; McMahon, S. J.; Rudan, N. M.; Yvon, A. -M.; Adams, A. W.; Sorcinelli, M. D.; Campbell, R.; Bonaccorsie, P.; Ansel, J. C.; Archer, D. R.; Wadsworth, P.; Armstrong, C. A.; Joshi, H. C. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 2002, 62, 4109-4114.
57. Zhou, J.; Gupta, K.; Aggarwal, S.; Aneja, R.; Chandra, R.; Panda, D.; Joshi, H. C. Brominated derivatives of noscapine are potent microtubule- interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol. 2003, 63(4), 799-807.
58. McIntosh, J. R. The role of microtubules in chromosome movement. In: Microtubules; Hyams, J. S.; Lloyd, C. W., Eds.; Wiley-Liss, Inc: New York, 1994, pp. 413-434.
59. Wordeman, L.; Mitchison, T. J. Dynamics of microtubule assembly in vivo. In: Microtubules; Hyams, J. S.; Lloyd, C. W., Eds.; Wiley-Liss, Inc: New York, 1994, pp. 287-302.
60. Mitchison, T. J.; Kirschner, M. Dynamic instability of microtubule growth. Nature 1984, 312, 237-242.
61. Kerssemakers, J. W. J.; Munteanu, E. L.; Laan, L.; Noetzel, T. L.; Janson, M. E.; Dogterom, M. Assembly dynamics of microtubules at molecular resolution. Nature 2006, 442, 709-712.
62. Margolis, R. L.; Wilson, L. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 1978, 13, 1-8.
63. Margolis, R. L.; Wilson, L. Microtubule treadmilling: What goes around comes around. Bioessays 1998, 20, 830-836.
64. Panda, D.; Miller, H. P.; Wilson, L. Rapid treadmilling of MAP-free brain microtubules in vitro and its suppression by tau. Proc. Natl. Acad. Sci. USA 1999, 96, 12459-12464.
65. Rodionov, V. I.; Borisy, G. G. Microtubule treadmilling in vivo. Science 1997, 275, 215-218.
66. Shaw, S. L.; Kamyar, R.; Ehrhardt, D. W. Sustained microtubule treadmilling in Arabidopsis cortical arrays. Science 2003, 300, 1715-1718.
67. Ehrhardt, D.; Shaw, S. Microtubule dynamics and organization in the plant cortical array. Annu. Rev. Plant Biol. 2006, 57, 859-975.
68. Chen, W.; Zhang, D. Kinetochore fibre dynamics outside the context of the spindle during anaphase. Nat. Cell Biol. 2004, 6, 227-231.
69. Nogales, E. Structural insights into microtubule function. Annu. Rev. Biophys. Biomol. Struct. 2001, 30, 397-420.
70. Lodish, H.; Baltimore, D.; Berk, A.; Zipursky, S. L.; Matsudaira, P.; Darnell, J. Molecular Cell Biology; 4th edition, Freeman, W. H., New York, 1999.
71. Wilson, L.; Jordan, M. A. Microtubule dynamics: taking aim at a moving target. Chem. Biol. 1995, 2, 569-573.
72. Caplow, M.; Fee, L. Concerning the chemical nature of tubulin subunits that cap and stabilize microtubules. Biochemistry 2003, 42, 2122-2126.
73. Panda, D.; Miller, H.; Wilson, L. Determination of the size and chemical nature of the stabilizing cap at microtubule ends using modulators of polymerization dynamics. Biochemistry 2002, 41, 1609-1617.
74. Salaycik, K. J.; Fagerstrom, C. J.; Murthy, K.; Tulu, U. S.; Wadsworth, P. Quantification of microtubule nucleation, growth and dynamics in wound-edge cells. J. Cell Sci. 2005, 118, 4113-4122.
75. Luduena, R. F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol. 1998, 178, 207-275.
76. McKean, P.; Vaughan, S.; Gull, K. The extended tubulin superfamily. J. Cell Sci. 2001, 114, 2723-2733.
77. Verdier-Pinard, P.; Wang, F.; Burd, B.; Angeletti, R.; Horwitz, S.; Orr, G. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 2003, 42, 12019-12027.
78. Feinstein, S.; Wilson, L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim. Biophys. Acta 2005, 1739, 268-279.
79. Itoh, T.; Hotani, H. Microtubule dynamics and the regulation by microtubule-associated proteins (MAPs). Biol. Sci. Space 2004, 18, 116-117.
80. Noetzel, T.; Drechsel, D. N.; Hyman, A. A.; Kinoshita, K. A comparison of the ability of XMAP215 and tau to inhibit the microtubule destabilizing activity of XKCM1. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2005, 360, 591-594.
81. Maney, T.; Wagenbach, M.; Wordeman, L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J. Biol. Chem. 2001, 276(37), 34753-34758.
82. Desai, A.; Verma, S.; Mitchison, T. J.; Walczak, C. E. Kin I kinesins are microtubule-destabilizing enzymes. Cell 1999, 96(1), 69-78.
83. Walczak, C. E. Ran hits the ground running. Nat. Cell. Biol. 2001, 3, E69-E70.
84. Walczak, C. E.; Mitchison, T. J.; Desai, A. XKCM1: a Xenopus kinesin-related protein that regulates microtubule dynamics during mitotic spindle assembly. Cell 1996, 84, 37-47.
85. Tirnauer, J. S.; Canman, J. C.; Salmon, E. D.; Mitchison, T. J. EB1 targets to kinetochores with attached polymerizing microtubules. Mol. Biol. Cell 2002, 13, 4308-4316.
86. Akhmanova, A.; Hoogenraad, C. C. Microtubule plus-end-tracking proteins: mechanisms and functions. Curr. Opin. Cell. Biol. 2005, 17, 47-54.
87. Maiato, H.; Fairley, E.; Rieder, C.; Swedlow, J.; Sunkel, C.; Earnshaw, W. C. Human CLASP1 is an outer kinetochore component that regulates spindle microtubule dynamics. Cell 2003, 113, 891-904.
88. Arnal, I.; Heichette, C.; Diamantopoulos, G.; Chretien, D. CLIP-170/tubulin-curved oligomers coassemble at microtubule ends and promote rescues. Curr. Biol. 2004, 14, 2086-2095.
89. Kita, K.; Wittmann, T.; Nathke, I. S.; Waterman-Storer, C. M. Adenomatous polyposis coli on microtubule plus ends in cell extensions can promote microtubule net growth with or without EB1. Mol. Biol. Cell. 2006, 17, 2331-2345.
90. Han, G.; Liu, B.; Zhang, J.; Zuo, W.; Morris, N. R.; Xiang, X. The Aspergillus cytoplasmic dynein heavy chain and NUDF localize to microtubule ends and affect microtubule dynamics. Curr. Biol. 2001, 11, 719-724.
91. Carazo-Salas, R.; Gruss, O. J.; Mattaj, I. W.; Karsenti, E. Ran-GTP coordinates regulation of microtubule nucleation and dynamics during mitotic-spindle assembly. Nat. Cell Biol. 2001, 3, 228-234.
92. Manna, T.; Thrower, D.; Miller, H. P.; Curmi, P.; Wilson, L. Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro. J. Biol. Chem. 2006, 281, 2071-2078.
93. Cassimeris, L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr. Opin. Cell Biol. 2002, 14, 18-24.
94. Abal, M.; Piel, M.; Bouckson-Castaing, V.; Mogensen, M.; Sibarita, J. B.; Bornens, M. Microtubule release from the centrosome in migrating cells. J. Cell Biol. 2002, 159, 731-737.
95. Delgehyr, N.; Sillibourne, J.; Bornens, M. Microtubule nucleation and anchoring at the centrosome are independent processes linked by ninein function. J. Cell Sci. 2005, 118, 1565-1575.
96. Baas, P.; Karabay, A.; Qiang, L. Microtubules cut and run. Trends Cell Biol. 2005, 15, 518-524.
97. McIntosh, J.; Grishchuk, E. L.; West, R. R. Chromosome-microtubule interactions during mitosis. Annu. Rev. Cell Dev. Biol. 2002, 18, 193-219.
98. Chang, W.; Gruber, D.; Chari, S.; Kitazawa, H.; Hamazumi, Y.; Hisanaga, S.; Bulinski, J. C. Phosphorylation of MAP4 affects microtubule properties and cell cycle progression. J. Cell Sci. 2001, 114(Pt 15), 2879-2887.
99. Ookata, K.; Hisanaga, S.; Bulinski, J. C.; Murofushi, H.; Aizawa, H.; Itoh, T. J.; Hotani, H.; Okumura, E.; Tachibana, K.; Kishimoto, T. Cyclin B interaction with microtubule-associated protein 4 (MAP4) targets p34cdc2 kinase to microtubules and is a potential regulator of M-phase microtubule dynamics. J. Cell. Biol. 1995, 128, 849-862.
100. Wilde, A.; Lizarraga, S. B.; Zhang, L.; Wiese, C.; Gliksman, N. R.; Walczak, C. E.; Zheng, Y. Ran stimulates spindle assembly by altering microtubule dynamics and the balance of motor activities. Nat. Cell Biol. 2001, 3, 221-227.
101. Rusan, N. M.; Fagerstrom, C. J.; Yvon, A. -M. C.; Wadsworth, P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol. Biol. Cell 2001, 12, 971-980.
102. Hayden, J. J.; Bowser, S. S.; Rieder, C. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in live newt cells. J. Cell Biol. 1990, 111, 1039-1045.
103. Maddox, P.; Desai, A.; Oegema, K.; Mitchison, T.; Salmon, E. Poleward microtubule flux is a major component of spindle dynamics and anaphase a in mitotic Drosophila embryos. Curr. Biol. 2002, 12, 1670-1674.
104. Mitchison, T. J. Poleward microtubule flux in the mitotic spindle; evidence from photoactivation of fluorescence. J. Cell Biol. 1989, 109, 637-652.
105. Wilson, P. J.; Forer, A. Effects of nanomolar taxol on crane-fly spermatocyte spindles indicate that acetylation of kinetochore microtubules can be used as a marker of poleward tubulin flux. Cell Motil. Cytoskeleton 1997, 37, 20-32.
106. Nicklas, R. B.; Ward, S. C.; Gorbsky, G. J. Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J. Cell Biol. 1995, 130, 929-939.
107. Li, X.; Nicklas, R. B. Mitotic forces control a cell-cycle checkpoint. Nature 1995, 373, 630-632.
108. Gorbsky, G. J. Cell cycle checkpoints: arresting progress in mitosis. BioEssays 1997, 19, 193-197.
109. Shelby, R. D.; Hahn, K. M.; Sullivan, K. F. Dynamic elastic behavior of alpha-satellite DNA domains visualized in situ in living human cells. J. Cell Biol. 1996, 135, 545-557.
110. Rieder, C.; Schultz, A.; Cole, R.; Sluder, G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J. Cell Biol. 1994, 127, 1301-1310.
111. Kelling, J.; Sullivan, K.; Wilson, L.; Jordan, M. A. Suppression of centromere dynamics by taxol in living osteosarcoma cells. Cancer Res. 2003, 63, 2794-2780.
112. Okouneva, T.; Hill, B. T.; Wilson, L.; Jordan, M. A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther. 2003, 2, 427-436.
113. Yu, H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr. Opin. Cell Biol. 2002, 14, 706-714.
114. Skoufias, D. A.; Andreassen, P.; Lacroix, F.; Wilson, L.; Margolis, R. L. Mammalian mad2 and bub1/bubR1 recognize distinct spindle-attachment and kinetochore-tension checkpoints. Proc. Natl. Acad. Sci. USA 2001, 10, 4492-4497.
115. King, J. M.; Nicklas, R. B. Tension on chromosomes increases the number of kinetochore microtubules but only within limits. J. Cell Sci. 2000, 113, 3815-3823.
116. Nicklas, R. B.; Campbell, M. S.; Ward, S. C.; Gorbsky, G. J. Tension-sensitive kinetochore phosphorylation in vitro. J. Cell. Sci. 1998, 111, 3189-3196.
117. Jordan, M. A.; Wilson, L. Microtubule polymerization dynamics, mitotic block, and cell death by paclitaxel at low concentrations. In: Taxane Anticancer Agents; Georg, G. I.; Chen, T. T.; Ojima, I.; Vyas, D. M., Eds; American Chemical Society: Washington, D.C., 1995, pp.138-153.
118. Jordan, M. A.; Wendell, K. L.; Gardiner, S.; Derry, W. B.; Copp, H.; Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996, 56, 816-825.
119. Weaver, B.; Cleveland, D. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005, 8, 7-12.
120. Hamel, E.; Covell, D. G. Antimitotic peptides and depsipeptides. Curr. Med. Chem. - Anticancer Agents 2002, 2, 19-53.
121. Hoffman, J. C.; Vaughn, K. C. Mitotic disrupter herbicides act by a single mechanism but vary in efficacy. Protoplasma 1994, 179, 16-25.
122. Jackson, S.; Singletary, K. Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. J. Nutr. 2004, 134, 2229-2236.
123. Lacey, E.; Gill, J. H. Biochemistry of benzimidazole resistance. Acta Trop. 1994, 56, 245-262.
124. Boder, G. B.; Paul, D. C.; Williams, D. C. Chlorpromazine inhibits mitosis of mammalian cells. Eur. J. Cell Biol. 1983, 31, 349-353.
125. Cann, J. R.; Hinman, N. D. Interaction of chlorpromazine with brain microtubule subunit protein. Mol. Pharmacol. 1975, 11, 256-267.
126. Lobert, S.; Ingram, J.; Correia, J. Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly. Cancer Res. 1999, 59, 4816-4822.
127. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. - Anti-Cancer Agents 2002, 2, 1-17.
128. Jimenez-Barbero, J.; Amat-Guerri, F.; Snyder, J. P. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem. - Anti-Cancer Agents 2002, 2(1), 91-122.
129. Jordan, M. A.; Thrower, D.; Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991, 51(8), 2212-2222.
130. Dhamodharan, R. I.; Jordan, M. A.; Thrower, D.; Wilson, L.; Wadsworth, P. Vinblastine suppresses dynamics of individual microtubules in living cells. Mol. Biol. Cell 1995, 6, 1215-1229.
131. Bai, R. B.; Pettit, G. R.; Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem. 1990b, 265, 17141-17149.
132. Jordan, M. A.; Wilson, L. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 1990, 29(11), 2730-2739.
133. Wilson, L.; Jordan, M. A.; Morse, A.; Margolis, R. L. Interaction of vinblastine with steady-state microtubules in vitro. J. Mol. Biol. 1982, 159,129-149.
134. Lobert, S.; Correia, J. Energetics of Vinca alkaloid interactions with tubulin. In: Methods in Enzymology; 2000, pp.77-103.
135. Na, G. C.; Timasheff, S. N. Stoichiometry of the vinblastine-induced selfassociation of calf brain tubulin. Biochem. Soc. Trans. 1980, 8(6), 1347-1354.
136. Na, G. C.; Timasheff, S. N. Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 1980, 19(7), 1347-1354.
137. Jordan, M. A.; Margolis, R. L.; Himes, R. H.; Wilson, L. Identification of a distinct class of vinblastine binding sites on microtubules. J. Mol. Biol. 1986, 187, 61-73.
138. Singer, W. D.; Jordan, M. A.; Wilson, L.; Himes, R. H. Binding of vinblastine to stabilized microtubules. Mol. Pharmacol. 1989, 36(3), 366-370.
139. Panda, D.; DeLuca, K.; Williams, D.; Jordan, M. A.; Wilson, L. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high affinity binding ot microtubule ends. Proc. Natl. Acad. Sci. USA 1998, 95, 9313-9318.
140. Toso, R. J.; Jordan, M. A.; Farrell, K. W.; Matsumoto, B.; Wilson, L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 1993, 32(5), 1285-1293.
141. Derry, W. B.; Wilson, L.; Jordan, M. A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995, 34, 2203-2211.
142. Kamath, K.; Jordan, M. A. Suppression of microtubule dynamics by epothilone B in living MCF7 cells. Cancer Res. 2003, 63, 6026-6031.
143. Yvon, A. -M.; Wadsworth, P.; Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 1999, 10, 947-949.
144. Nogales, E.; Wolf, S. G.; Khan, I. A.; Luduena, R. F.; Downing, K. A. Structure of tubulin at 6.5A and location of the taxol-binding site. Nature 1995, 375, 424-427.
145. Jordan, M. A.; Toso, R. J.; Thrower, D.; Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA 1993, 90, 9552-9556.
146. Gaitanos, T.; Buey, R.; Diaz, J.; Northcote, P.; Teesdale-Spittle, P.; Andreu, J.; Miller, J. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res. 2004, 64, 5063-5067.
147. Pryor, D. E.; O'Brate, A.; Bilcer, G.; Diaz, J. F.; Wang, Y.; Wang, Y.; Kabaki, M.; Jung, M. K.; Andreu, J. M.; Ghosh, A. K.; Giannakakou, P.; Hamel, E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002, 41, 9109-9115.
148. Goncalves, A.; Braguer, D.; Kamath, K.; Martello, L.; Briand, C.; Horwitz, S.; Wilson, L.; Jordan, M. A. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. USA 2001, 98, 11737-11741.
149. Wilson, L.; Jordan, M. A. Pharmacological probes of microtubule function. In: Microtubules; Hyams, J.; Lloyd, C., Eds.; John Wiley and Sons, Inc.: New York, 1994. pp. 59-84.
150. Downing, K. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell. Dev. Biol. 2000, 16, 89-111.
151. Chen, J. -G.; Horwitz, S. B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 2002, 62, 1935-1938.
152. Paoletti, A.; Giocanti, N.; Favaudon, V.; Bornens, M. Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis. J. Cell Sci. 1997, 110, 2403-2415.
153. Jordan, M. A.; Wilson, L. The use and action of drugs in analyzing mitosis. In: Methods in Cell Biology; Academic Press, 1999. pp. 267-295.
154. Jordan, M. A.; Wilson, L. The use of drugs to study the role of microtubule assembly dynamics in living cells. In: Molecular Motors and the Cytoskeleton, Methods in Enzymology; Vallee, R., Ed.; Academic Press, 1998. pp. 252-276.
155. Ngan, V.; Bellman, K.; Hill, B.; Wilson, L.; Jordan, M. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol. Pharmacol. 2001, 60, 225-232.
156. Holwell, S.; Cooper, P.; Thompson, M.; Pettit, G. R.; Lippert, L. W., 3rd.; Martin, S.; Bibby, M. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res. 2002, 22, 3933-3940.
157. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002, 99, 2060-2069.
158. Tozer, G. M.; Prise, V. E.; Wilson, J.; Cemaza, M.; Shan, S.; Dewhirst, M. W.; Barber, P. R.; Vojnovic, B.; Chaplin, D. J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001, 61, 6413-6422.
159. Prise, V. E.; Honess, D. J.; Stratford, M. R.; Wilson, J.; Tozer, G. M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 2002, 21, 717-726.
160. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R.; Chaplin, D. J.; Hill, S. A. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002, 62, 7247-7253.
161. Merchan, J.; Jayaram, D. R.; Supko, J. G.; He, X.; Bubley, G.; Sukhatme, V. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int. J. Cancer 2005, 113, 490-498.
162. Holwell, S.; Hill, B.; Bibby, M. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. J. Cancer 2001, 84, 290-295.
163. Bocci, G.; Nicolaou, K.; Kerbel, R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002, 62, 6938-6943.
164. Hotchkiss, K. A.; Ashton, A. W.; Mahmood, R.; Russell, R. G.; Sparano, J. A.; Schwartz, E. L. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol. Cancer Ther. 2002, 1(13), 1191-1200.
165. Pasquier, E.; Honore, S.; Pourroy, B.; Jordan, M.; Lehmann, M.; Briand, C.; Braguer, D. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005, 65, 2433-2440.
166. Pourroy, B.; Honore, S.; Pasquier, E.; Bourgarel-Rey, V.; Kruczynski, A.; Briand, C.; Braguer, D. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 2006, 66, 3256-3263.
167. Liao, G.; Nagasaki, T.; Gundersen, G. G. Low concentrations of nocodazole interfere with fibroblast locomotion without significantly affecting microtubule level: implications for the role of dynamic microtubules in cell locomotion. J. Cell Sci. 1995, 108, 3473-3483.
168. Pasquier, E.; Honore, S.; Braguer, D. Microtubule-targeting agents in angiogenesis: Where do we stand? Drug Resist. Updat. 2006, 9, 74-86.